EL7.AI
StocksMedium•14 November 2026•
2 min read

Cerenome Shares Jump 41.43% Ahead of Third-Quarter Results Due Nov. 16

Key Facts

1CNSY shares rose 41.43% on Nov. 13, 2026, and closed at $1.0897.
2Cerenome set Nov. 16, 2026, as the date for its third-quarter results, according to its Nov. 12 statement.
3The company said its Aetna agreement brought it to contracts with about 85% of U.S. private insurers, representing nearly 190 million covered lives.
4The operating loss was $9.1 million in the second quarter of 2026, compared with $1.5 million in the second quarter of 2025.

Cerenome said in a statement dated Nov. 12 that third-quarter results would be released on Nov. 16, 2026, two days after the article was published on Nov. 14. The company said the results call would present data from the ReSPECT-LM trial, which was scheduled to be presented at the SNO conference on Nov. 13, along with a commercial update on CNSide. CNSY shares closed at $0.7705 on Nov. 12, according to EL7 data. The stock then rose 41.43% on Nov. 13, closing at $1.0897, according to historical market data cited by Investing.com. The move came ahead of the results announcement date set by the company.

As part of CNSide's commercial expansion, Cerenome said on Nov. 4 that its agreement with Aetna increased the number of U.S. private insurers with which it contracts to about 85% of the market, representing nearly 190 million covered lives. The update offers a picture of the insurance coverage the company said it had secured, as investors await third-quarter results. In second-quarter results published on Aug. 14, the company reported $0.4 million in grant revenue from CPRIT to support REYOBIQ development, compared with $1.4 million in the same period of 2025. The company recorded an operating loss of $9.1 million in the second quarter of 2026, compared with a loss of $1.5 million a year earlier. The company attributed the wider operating loss mainly to expanding CNSide's commercial operations and funding the REYOBIQ trial.

Cerenome's net loss in the second quarter of 2026 was about $9.0 million, or $1.31 per basic share, according to the company's results. In the second quarter of 2025, the company reported net income of $5.2 million, or $0.62 per basic share. These figures provide prior financial context ahead of the third-quarter announcement, but relate to a different period from the results the company said it would report on Nov. 16. The company also said data from the ReSPECT-GBM trial were expected in the first quarter of 2027, after completion of Phase 2 enrollment. The third-quarter results date announced by the company remains the next scheduled event for investors.

Open on chart